Evidence map›Paper›PMID 39844366›Full record

ArticleActa neuropsychiatrica2025

Limited evidence of association between dysregulated immune marker levels and telomere length in severe mental disorders.

Monica B E G Ormerod, Thor Ueland, Monica Aas, Gabriela Hjell, Linn Rødevand, Linn Sofie Sæther, Synve Hoffart Lunding, Ingrid Torp Johansen, Vid Mlakar, Dimitrios Andreou and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Acta neuropsychiatrica, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Monica B E G OrmerodDivision of Mental Health and Addiction, Oslo University Hospital, Oslo, Norway.ORCID https://orcid.org/0000-0002-8183-5530
Thor UelandInstitute of Clinical Medicine, University of Oslo, Oslo, Norway.ORCID https://orcid.org/0000-0001-5005-0784
Monica AasSocial, Genetic and Developmental Psychiatry Centre, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.ORCID https://orcid.org/0000-0002-2338-5826
Gabriela HjellDepartment of Psychiatry, Ostfold Hospital, Graalum, Norway.ORCID https://orcid.org/0000-0002-1257-6731
Linn RødevandInstitute of Clinical Medicine, University of Oslo, Oslo, Norway.ORCID https://orcid.org/0000-0001-5967-6601
Linn Sofie SætherDivision of Mental Health and Addiction, Oslo University Hospital, Oslo, Norway.ORCID https://orcid.org/0000-0002-2185-8300
Synve Hoffart LundingInstitute of Clinical Medicine, University of Oslo, Oslo, Norway.ORCID https://orcid.org/0000-0002-3342-7997
Ingrid Torp JohansenInstitute of Clinical Medicine, University of Oslo, Oslo, Norway.ORCID https://orcid.org/0000-0001-7976-1395
Vid MlakarSocial, Genetic and Developmental Psychiatry Centre, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.ORCID https://orcid.org/0009-0000-2812-621X
Dimitrios AndreouDivision of Mental Health and Addiction, Oslo University Hospital, Oslo, Norway.ORCID https://orcid.org/0000-0003-4735-3383
Torill UelandDivision of Mental Health and Addiction, Oslo University Hospital, Oslo, Norway.ORCID https://orcid.org/0000-0002-8638-1152
Trine V LagerbergDivision of Mental Health and Addiction, Oslo University Hospital, Oslo, Norway.ORCID https://orcid.org/0000-0003-3579-0789
Ingrid MelleDivision of Mental Health and Addiction, Oslo University Hospital, Oslo, Norway.ORCID https://orcid.org/0000-0002-9783-548X
Srdjan DjurovicDepartment of Medical Genetics, Oslo University Hospital and University of Oslo, Oslo, Norway.ORCID https://orcid.org/0000-0002-8140-8061
Ole A AndreassenDivision of Mental Health and Addiction, Oslo University Hospital, Oslo, Norway.ORCID https://orcid.org/0000-0002-4461-3568
Nils Eiel SteenDivision of Mental Health and Addiction, Oslo University Hospital, Oslo, Norway.ORCID https://orcid.org/0000-0001-6442-1179

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveAccelerated ageing indexed by telomere attrition is suggested in schizophrenia spectrum- (SCZ) and bipolar disorders (BD). While inflammation may promote telomere shortening, few studies have investigated the association between telomere length (TL) and markers of immune activation and inflammation in severe mental disorders.

methodsLeucocyte TL defined as telomere template/amount of single-copy gene template (T/S ratio), was determined in participants with SCZ (

resultsA positive association between levels of soluble tumour necrosis factor receptor 1A (sTNF-R1) and TL in SCZ (

conclusionThere was limited evidence of association between immune markers and TL in SCZ and BD. The results provide little support for involvement of immune dysregulation, as reflected by current systemic markers, in telomere attrition-related accelerated ageing in severe mental disorders.

Indexed as

Bipolar DisorderSchizophreniaTelomereTelomere HomeostasisTelomere ShorteningAdultBiomarkersFemaleHumansInflammationLeukocytesMaleMiddle AgedBiomarkersAgeingBipolar disorderCytokinesSchizophreniaTelomere

Identifiers

PMID39844366
PMCPMC13130312

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.